Cure My Disease

Don't miss your cure!

 Log in / Sign up

Quick-Relief nasal spray combo tested for kids with stubborn allergies

NCT ID NCT07593898

Symptom relief Sponsor: Dr. Behcet Uz Children's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding a decongestant nasal spray for the first 5 days to standard steroid spray treatment helps children with persistent allergic rhinitis feel better faster. 76 children aged 4-18 were randomly assigned to receive either steroid spray alone for 4 weeks or steroid spray plus the decongestant for the first 5 days. The researchers measured changes in nasal symptoms, airflow, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mometasone furoate nasal spray and oxymetazoline nasal spray
What this could lead to
If successful, this approach could offer quicker symptom relief for children with persistent allergies, improving their quality of life and treatment adherence.
What could go wrong
This is a small, completed Phase 4 trial with only 76 children. The decongestant is only used for 5 days, and long-term benefits or risks are not assessed. Results may not apply to all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

76 people

The number who actually took part.

Started

Jan 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged 4 to 18 years * Diagnosis of moderate-to-severe persistent allergic rhinitis according to ARIA guidelines * Ability to comply with study procedures * Written informed consent obtained from parents or legal guardians Exclusion Criteria: * Mechanical nasal obstruction (nasal polyposis, severe septal deviation, or adenoid hypertrophy) * Acute upper respiratory tract infection within the previous 2 weeks * Active smoking or significant passive smoke exposure * Current use of allergic rhinitis medications * Use of intranasal corticosteroids within the previous 3 months * Inability to comply with study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Persistent allergic rhinitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Medication Adherence Nasal Obstruction perennial allergic rhinitis Rhinitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Persistent allergic rhinitis

Contacts and locations

Locations

  • Dr. Behcet Uz Pediatric Diseases and Surgery Training and Research Hospital

    Izmir, 35180, Turkey (Türkiye)